SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Chelsea
Therapeutics International, Ltd. in Connection with the Proposed Sale of the
Company to H. Lundbeck A/S
STEVENSON, Md. -- May 8, 2014
The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty to current shareholders of Chelsea Therapeutics International,
Ltd. (“Chelsea” or the “Company”) (NasdaqCM: CHTP) and other violations of
state law by the board of directors of Chelsea relating to the proposed buyout
of the Company by H. Lundbeck A/S (“Lundbeck”).
Under the terms of the transaction, public shareholders of Chelsea would
receive $6.44 in cash, and up to $1.50 per share in a Contingent Value Right,
for each share of Chelsea they own. According to Yahoo! Finance, at least one
analyst has set a target price for Chelsea stock at $12.00 per share. The
firm’s investigation seeks to determine, among other things, whether the
Company’s board of directors breached their fiduciary duties by failing to
maximize shareholder value before agreeing to enter into this transaction, and
whether Lundbeck is underpaying for Chelsea shares.
If you currently own common stock of Chelsea and would like to learn more
about the investigation being conducted by Brower Piven, without cost or
obligation to you, click here:
You may also request more information by contacting Brower Piven either by
email at email@example.com or by telephone at (410) 415-6616. Attorneys
at Brower Piven together have more than a century of experience litigating
securities and other class action cases.
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Charles J. Piven, 410-415-6616
Press spacebar to pause and continue. Press esc to stop.